Leading Scientists Demonstrate How Seer’s Proteograph Product Suite Advances Cardiovascular and Neurodegenerative Research at US HUPO 2026
Rhea-AI Summary
Seer (NASDAQ: SEER) will participate in US HUPO 2026 in St. Louis, Feb 21–25, showcasing the Proteograph Product Suite across posters, oral sessions, and a breakfast symposium on Feb 24. Presentations span cardiovascular disease, neurodegeneration, aging biology, oncology, and population-scale proteomics, highlighting deep, scalable nanoparticle-enabled proteomics.
Speakers include Sasha A. Singh, Nathan Basisty, Bruce Wilcox, and Mozhgan Boroumand; Singh reports quantifying >5,000 proteins from 75 µL plasma per sample.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, SEER gained 1.49%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
SEER slipped 1.46% while close peers showed mixed moves (e.g., ADAG -0.6%, FBIO -1.43%, CGEN +1.19%, IOBT +1.77%, KALA -3.55%). No peers appeared in momentum scanners, suggesting today’s action is more stock-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 05 | Earnings date notice | Neutral | +2.3% | Announced timing for Q4 and full-year 2025 earnings release and call. |
| Dec 01 | Platform validation study | Positive | -1.0% | Nature Genetics study validated Proteograph for population-scale proteomics and biomarker work. |
| Nov 07 | HUPO 2025 data | Positive | -3.2% | Announced extensive HUPO 2025 presentations showcasing Proteograph in multiple disease areas. |
| Nov 06 | Q3 2025 earnings | Positive | -0.5% | Reported higher revenue, improved loss metrics, and reiterated full-year 2025 guidance. |
| Oct 29 | Investor conferences | Neutral | -3.1% | Outlined participation in two November 2025 healthcare investor conferences. |
Recent history shows SEER often trading lower after positive scientific or platform-validation news, indicating a pattern of price weakness on otherwise constructive updates.
Over the last few months, Seer has balanced scientific validation with ongoing commercial ramp. A Nov 2025 Q3 update showed growing revenue and reiterated 2025 guidance, yet the stock eased slightly. Scientific milestones, including a Nature Genetics validation of Proteograph and broad data at HUPO 2025, were followed by negative price reactions. Today’s US HUPO 2026 news continues the theme of expanding Proteograph adoption across major disease areas and large-scale cohorts.
Market Pulse Summary
This announcement highlights extensive use of Seer’s Proteograph suite at US HUPO 2026, with more than a dozen presentations spanning cardiovascular disease, neurodegeneration, oncology, and aging biology. It reinforces themes from prior HUPO and Nature Genetics updates that showcased deep, scalable proteomics in large cohorts. Investors may watch for evidence that this scientific traction converts into revenue growth in upcoming financial results and for continued third-party data validating clinical and population-scale workflows.
Key Terms
proteomics medical
mass spectrometry technical
multi-omics technical
biomarkers medical
AI-generated analysis. Not financial advice.
Nathan Basisty, Sasha Singh, Bruce Wilcox, and Mozhgan Boroumand among scientific leaders presenting unique proteomics-enabled biological insights
REDWOOD CITY, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced its participation in the 2026 U.S. Human Proteome Organization (US HUPO) Annual Conference, taking place February 21-25 in St. Louis, Missouri. At the meeting, researchers will demonstrate how Seer’s Proteograph® Product Suite is enabling them to tackle complex questions in major disease areas, while supporting the scaling requirements needed for clinical and population health applications.
US HUPO has emerged as an important venue for evaluating how new proteomic technologies perform when applied to real-world research challenges. At US HUPO 2026, Seer will be featured across more than a dozen scientific presentations spanning posters, oral sessions, and plenary talks, reflecting the growing adoption of nanoparticle-enabled proteomics across translational and population-scale research. This year’s presentations span cardiovascular disease, neurodegeneration, aging biology, oncology, and computational advances, underscoring how deep, scalable proteomics is helping bridge laboratory discovery with human health outcomes.
Attendees can connect with the Seer team at Booth #18, explore poster presentations featuring biological insights enabled by the Proteograph Product Suite, and attend a breakfast symposium highlighting breakthrough findings in cardiovascular disease research.
"The work being presented at US HUPO reflects a broader shift in proteomics toward deeper, more scalable, and more reproducible mass spectrometry measurement of the human proteome that is enabled by the Proteograph Product Suite," said David Horn, President and Chief Financial Officer at Seer. "As researchers apply the Proteograph solution to their complex disease models and large-scale cohorts, we are seeing strong validation of the Proteograph’s scientific impact and its strategic importance to advancing translational research at scale.”
Seer Breakfast Symposium
Nanoparticle-Enabled Plasma Proteomics of a Mouse Atherosclerosis Model
Date: Tuesday, February 24 | Time: 7:15–8:15 a.m. CT | Location: Room Grand GH
Speaker: Sasha A. Singh, PhD, Assistant Professor of Medicine, Harvard Medical School
In Tuesday’s symposium, Dr. Singh will present how her laboratory applied the Proteograph Product Suite to deeply profile plasma in a murine model of atherosclerosis, addressing long-standing challenges in detecting low-abundance proteins from small-volume samples. Using just 75 µL of plasma per sample, the workflow enabled reproducible quantification of more than 5,000 proteins, representing more than a tenfold increase in proteome depth compared with conventional approaches.
US HUPO Plenary Session Highlight
Nathan Basisty, PhD, NIH Distinguished Scholar and Tenure Track Investigator at the National Institute on Aging, will present during the Robert J. Cotter New Investigator Award Plenary Session on Tuesday, February 24 (8:30–9:05 a.m. CT). His talk, Paving the Road to Translational Geroscience with Proteomics, will explore how advances in proteomic technologies are accelerating the translation of aging biology into biomarkers and therapeutic strategies.
Additional Scientific Presentations Featuring Seer Technology
Seer-enabled research will be featured across a broad set of oral presentations, plenary sessions, and posters throughout US HUPO 2026, highlighting the application of deep, scalable proteomics to cardiovascular disease, neurodegeneration, oncology, aging biology, and population-scale workflows.
Invited Speaker Presentations
- Pathways and Pitfalls in Translating Multi-Omics Discoveries into a Protein-Based LDT for Lung Cancer
Bruce Wilcox, PrognomiQ
February 24 | 9:15 AM | Room Grand DE
- Linking Tissue-Specific Senescence Burden to Circulating Protein Signatures Using a Novel Nanoparticle-Based Enrichment Workflow
Mozhgan Boroumand, National Institute on Aging, NIH
February 24 | 9:57 AM | Room Grand DE
Oral and Poster Presentations
- Unbiased Deep Proteomic Profiling of Conditioned Media and Cerebrospinal Fluid Using a Nanoparticle-Based Workflow
Presenter: A. Gajadhar | Poster Session 1 | February 23, 4:30–6:30 PM CT - Systematic Proteomic Architecture of Neurodegeneration Reveals Translation and Vesicular Dysregulation as Upstream Drivers of Neuronal Decline
Presenter: A. Siddiqui | Poster Session 1 | February 23, 4:30–6:30 PM CT - Evaluating Nanoparticle-Based Enrichment of Cell Lysates for Automated, Global Proteome Analysis
Presenter: E. Stancliffe | Poster Session 1 | February 23, 4:30–6:30 PM CT
- Addressing the Plasma Proteomics Needs of Large-Scale Clinical Cohorts
Presenter: C. Kempf | Poster Session 1 | February 23, 4:30–6:30 PM CT - Accelerating Biomarker Discovery with High-Depth, Whole Patient Multimodal Proteomics and Transcriptomics
Presenter: D. Gutierrez | Poster Session 1 | February 23, 4:30–6:30 PM CT
- From Peaks to Power: Context-Driven Determinants of Accuracy in Biologically Resolved Proteomics
Presenter: L. Cantrell | Poster Session 2 | February 24, 4:30–6:30 PM CT - A Cloud-Native Pipeline Enabling Fast, Sensitive, and Accurate Quantitative DIA Proteomics for Thousands of Samples
Presenter: S. Just | Poster Session 2 | February 24, 4:30–6:30 PM CT - Comprehensive Plasma Proteomic Analysis of Systemic Changes Following Chemotherapy in Breast Cancer Patients
Presenter: L. Herring | Poster Session 2 | February 24, 4:30–6:30 PM CT - Aging-Associated Plasma Proteome Changes in Healthy Non-Human Primates
Presenter: D. Key Planas | Poster Session 2 | February 24, 4:30–6:30 PM CT - An Optimized Workflow for Plasma Proteomics
Presenter: D. Key Planas | Poster Session 2 | February 24, 4:30–6:30 PM CT
Together, these presentations reflect the expanding role of Proteograph-enabled workflows in advancing biological insight across disease areas while supporting reproducible, high-throughput proteomics at scale.
About Seer, Inc.
Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics, delivering insights with a scale, speed, precision and reproducibility previously unattainable. Seer's Proteograph® Product Suite integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables and advanced analytical software to overcome the limitations of traditional proteomic methods. Seer's products are for research use only and are not intended for diagnostic procedures. For more information, visit www.seer.bio.
For more information, please visit Booth #18 at US HUPO 2026 or contact us at pr@seer.bio.
Media Contact:
Patrick Schmidt
pr@seer.bio
Investor Contact:
Kelly Gura
investor@seer.bio
FAQ
What will Seer present at US HUPO 2026 (SEER) in St. Louis on Feb 24, 2026?
How many proteins did Sasha A. Singh quantify using Proteograph at US HUPO 2026 (SEER)?
Which disease areas will Seer (SEER) showcase at the US HUPO 2026 conference?
When and where is the Seer breakfast symposium at US HUPO 2026 for SEER investors or attendees?
Which Seer (SEER) researchers are presenting plenary or invited talks at US HUPO 2026?
How is the Proteograph Product Suite positioned for large-scale clinical and population studies, according to Seer (SEER)?
